Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. (July 2022)

• Record Type: Journal Article
• Authors: Jansen, Anouk M.E.; Muilwijk, Eline W.; van der Velden, Walter J.F.M.; Maertens, Johan A.; Aerts, Robina; Colbers, Angela; Burger, David; Verweij, Paul E.; ter Heine, Rob; Blijlevens, Nicole M.A.; Brüggemann, Roger J.M.
• Is Part Of: Clinical microbiology and infection. Volume 28:Number 7(2022)
• Page Start: 1003
• Page End: 1009
• Publication Date: 2022-07
• Subjects: Absolute bioavailability -- Azoles -- Haematology -- Intestinal mucositis -- Population pharmacokinetics; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2022.01.029
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Objectives: This study aimed to describe the absolute oral bioavailability of the solid oral formulation of posaconazole and the impact of severe intestinal mucositis in haematology patients. This study also aimed to describe posaconazole protein binding in haematology patients. Methods: A pharmacokinetic study was performed of patients receiving induction chemotherapy or a haematopoietic cell transplantation who were randomized to receive 7 days of intravenous posaconazole therapy followed by 9 days of oral therapy, or vice versa. Patients received a posaconazole licensed dose until day 12, after which a reduced once-daily dose of 200 mg was given. At days 7, 12, and 16, blood samples were obtained for pharmacokinetic curves, and trough samples were collected on all other days. Total and unbound posaconazole pharmacokinetics were analyzed by population pharmacokinetic modelling. The presence of severe intestinal mucositis was assessed by plasma citrulline levels and analyzed as a binary covariate using 10 μmol/L as the cut-off. Monte Carlo simulations were performed to simulate posaconazole exposure at a steady state. Results: Twenty-three patients were included for analysis, with 581 total posaconazole concentrations and 91 paired unbound concentrations. Absolute bioavailability in the final model was estimated at 51.4% (percentage relative standard error (%RSE): 56.5) and 67.6% (%RSE: 75.0) in patients with and without severe intestinal mucositis, respectively. Posaconazole unbound fraction was estimated at 2.7% (%RSE: 3.9). Discussion: Posaconazole bioavailability is reduced in haematological patients with severe intestinal mucositis, requiring an increase in oral posaconazole dose to 400 mg twice daily on day 1, followed by 400 mg once daily or a switch to intravenous therapy.